Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies
Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) administered over 24 weeks for treatment of active psoriatic arthritis.
Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p < 0.05).
"We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future, said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Science retracts NASA arsenic bacteria paper after years of controversy
In 2010, in the waters of Mono Lake in California, NASA-funded scientists claimed to have found a microbe called GFAJ-1 they said rewrote biology. It had allegedly replaced the phosphorus in its DNA with the toxic element arsenic. The announcement, made at a high-profile press conference on December 2 that year, stunned the world. The findings, soon published in the journal Science, hinted that life could rely on a radically different chemistry. Lead author and microbial geobiologist Felisa Wolfe-Simon declared, 'Life as we know it may be due for a revision.' Speculation surged: had NASA stumbled onto alien biology? Set the ball rolling On July 24 this year, Science announced that it would be retracting the GFAJ-1 paper, nearly 15 years after its splashy debut, citing shifting editorial standards and lingering public confusion. 'It's important to have any groundbreaking work independently evaluated before drawing far-reaching conclusions,' University of Minnesota synthetic biologist Kate Adamala said. 'We want the public to be excited, but the message must match the strength of the data.' Mainstream media amplified the drama. One headline read: 'NASA Discovers Life Not As We Know It'. Ivan Oransky, co-founder of Retraction Watch, a site that tracks withdrawn papers and promotes research transparency, and executive director of The Centre for Scientific Integrity, saw the media blitz as pivotal. 'Without the hype, this paper might never have been retracted.' He pointed to NASA's style of communication as a key factor in the storm that followed in 2010. 'Historically, NASA hasn't always had a respectful relationship with journalists,' he said. 'They're great at promoting themselves, and sometimes at overselling.' Peer review in public To the people at large, the prospect of arsenic life hinted at alien biochemistry. But for many scientists, the GFAJ-1 paper raised more questions than answers. Critics began pointing out that arsenate is unstable in water, so its role in DNA seemed chemically implausible. 'If true, this would have overturned nearly a century of data, but nothing in the chemistry suggested it was possible,' Steven Benner, an early critic and chemistry professor at University of Florida said. Others were initially intrigued. 'I was very excited and impressed. It was a big deal in the origins community,' Adamala, then a graduate student, said. But like many, her enthusiasm waned as flaws emerged. Microbiologist Rosemary Redfield became a leading critic and one of the first replicators to disprove the findings. 'It's a fine example of how easy it is for scientists to be misled by an attractive hypothesis and of why we need both formal peer review and informal outside scrutiny.' By late December, the backlash gained traction. Blogs and Twitter (now turned the paper into a case study on post-publication peer review. Sheila Jasanoff, professor of science and technology studies at Harvard, noted that while such public spaces can foster valuable crowd-sourced peer review, they also risk overreach. 'These days science, like true crime, has spilled outside the constraints of officially authorised review. However, like all forms of democratisation, such informal policing can run out of control if it is driven by a mob mentality that is out to shame or undermine a researcher or a research program.' The original team stood by their findings — but by now the tone had shifted. Evidence falls apart Over the next 18 months, multiple labs tested the paper's core assertion. In 2012, Science published two studies that refuted it. Redfield's team found no arsenate in GFAJ-1's DNA. Tobias Erb's group confirmed the microbe still needed phosphorus to grow, i.e. it hadn't rewritten biology, just tolerated low-phosphate conditions. Wolfe-Simon maintained that her team's methods showed arsenic was incorporated into DNA and were robust enough to rebut Benner's contamination claims. Science didn't retract or flag the paper, saying claims should be resolved by further research, not editorial action. And since no fraud was alleged, the rebuttals sufficed. 'The whole debate ends up circling around the semantics of words like 'error', 'fraud', 'misconduct,'' Oransky said. 'But this paper, let's be honest, has been understood as unreliable since at least 2012, if not earlier.' Why science took so long For Benner, the GFAJ-1 paper reflected differences in scientific perspectives. Biologists saw phosphorus as essential, chemists knew arsenate's instability, geologists accepted mineral substitutions, and astrobiologists embraced radical possibilities. 'It wasn't that reviewers were incompetent,' Benner said. 'They just didn't all speak the same scientific language.' He saw another deeper flaw. NASA's astrobiology community often relies on consensus panels that falter when no one challenges ideas outside their domain. 'Multidisciplinary science is essential,' he said, 'but when it's superficial, weak claims slip through. This wasn't peer review breaking down: it was different communities assuming they shared standards while working from very different assumptions.' Adamala echoed this concern: 'Young scientists in interdisciplinary fields should embrace continuous peer review, as reliance on collaborators' expertise can miss flaws that later scrutiny might catch.' Correction sans closure 'They're right to retract a paper whose high-profile conclusions were entirely wrong,' Redfield said. One senior researcher noted that the Committee on Publication Ethics (COPE) guidelines, which many journals have adopted as a measure to improve research integrity, justify a retraction if the findings are unreliable. Here, multiple labs found phosphate in the arsenate medium, undermining the paper's core claim that the microbe grew by substituting arsenic for phosphorus. 'The growth experiments at the heart of the paper were flawed,' the researchers said. 'Even if it was an honest mistake, the core conclusions didn't hold up.' Adamala said that it's a good example of self-regulation in science. 'Slowly but surely, mistakes do get corrected.' Oransky was more measured: 'Science is now acting on an expanded definition of retraction that's consistent with what's been possible for a long time, but rarely used.' Not everyone sees it as black and white. Jasanoff warned that retractions can erase the very messiness that makes science work. 'Rather than draw hard lines between truth and error, science advances through open debate,' she said. 'It's better to preserve a record that shows how scientists test, challenge, and refine their ideas, even when plausible claims later prove wrong.' Benner, for his part, expressed worry that broadening retraction policies could weaken the informal scrutiny that exposed the paper's flaws, raising questions about balancing error correction with preserving the scientific process. Today, the whole saga has transformed into a cautionary tale. Adamala said the controversy may have cast a shadow over exotic chemistry research in astrobiology, making scientists more cautious about bold claims. Who pays the price? Wolfe-Simon's rise and fall was swift. In 2010, she was hailed for a potential revolution in biology. Two years later, she quietly exited both NASA and mainstream science, her research career derailed by controversy and lack of funding. 'Good scientists would have responded by getting back into the lab and doing the necessary follow-up work. But these authors still don't admit mistakes,' Redfield said, pointing to their rebuttal letter in response to the retraction. Ariel Anbar, a coauthor of the now retracted paper, said, 'Science cited no misconduct or specific mistake. We stand firmly by the integrity of our data.' He also criticised the journal for not sharing a blog post it published regarding the retraction with the authors, calling it a breach of COPE guidelines. Oransky disagreed: 'What guideline is this referring to? Furthermore, standing by your data doesn't mean there aren't errors in it.' Anbar also said the team rejected 'the alleged error' and that it was raised in 2011 and rebutted in a peer-reviewed exchange. 'They may reject it,' Oransky replied, 'but that seems to be the rationale for the retraction.' Nonetheless, Oransky also said Science's retraction notice could have been clearer. He explained that retractions often imply misconduct, so when Science called the paper unreliable but not unethical, it still put the authors on the defensive. 'You can see that here, they're saying: 'But there was no misconduct. No clear error.'' Jasanoff said she doesn't see it completely as an individual failure. She argued that the unusually long delay until retraction may reflect less a concern with scientific uncertainty and more with a broader institutional tendency to manage reputation, especially in an era of heightened fears over misinformation. Wolfe-Simon's arc underscored a stark truth: high-risk discoveries bring both acclaim and vulnerability. When science goes public, its failures play out just as visibly as its triumphs, leaving lasting questions about how to correct course without crushing the people behind the work. A slow machine Peer-reviewers cleared GFAJ-1 and media hype propelled it, but shifting editorial norms more than new data undid it 15 years later. Oransky singled out Science's editor-in-chief, Holden Thorp, for leading that shift. 'Other journals have done it, but he's been consistently engaged in a way that encourages open conversation, no matter whether people agree with specific decisions or not.' That kind of editorial openness, he added, may be the real legacy of the arsenic life saga. Jasanoff, however, cautioned that every retraction risks erasing the visible, iterative debate that builds trust. 'It is better for people to understand that science moves through trial and error, and gradual self-correction. It is not a binary. All science is provisional.' Benner drew a parallel to the 1976 Viking missions, where a premature 'no organics, no life' verdict in Science stifled debate. 'Calling the ballgame early had an unfortunate result. It prevented the dialectic the scientific process needs.' The arsenic life case endures not because of its flawed claim, but for what it revealed about the pressures shaping modern science: how spectacular findings — especially from institutions like NASA — can short-circuit scrutiny, and how correcting course means confronting the very systems that made such claims irresistible in the first place. Anirban Mukhopadhyay is a geneticist by training and science communicator from Delhi.
Time of India
7 hours ago
- Time of India
How changing the order of your meals can lower blood sugar spikes: Know its benefits
Recent research and expert advice show that in Indian meals, the sequence matters. The order you eat your food can help control blood sugar. Start with non‑starchy vegetables like salad or stir-fried greens, then move on to protein and good fats like dal, paneer, eggs, nuts or seeds. Finally, finish with carbohydrates such as roti, rice, or millet. Eating this way slows down digestion and helps avoid sudden glucose spikes. It also boosts insulin response, helps you feel full longer, and supports better metabolic health. Perfect for people with pre‑diabetes, type 2 diabetes, or anyone wanting steadier energy levels What is meal sequencing and how it works in controlling blood sugar Meal sequencing refers to eating your meal components in a specific order: Vegetables (especially non‑starchy/fiber-rich) Proteins and healthy fats Carbohydrates (grains, starches, or sweets) Eating fiber and protein first slows gastric emptying and reduces the rate at which carbohydrates are absorbed. This helps reduce post-meal blood sugar spikes. How meal sequencing works 1. GLP‑1 release and insulin efficiency: Protein and fat eaten first increase incretin hormones like GLP‑1, triggering better insulin response and slowing down glucose absorption 2. Delayed gastric emptying: Starting meals with fibre and fats slows digestion, leading to a gradual blood sugar rise rather than a sudden spike 3. Improved insulin sensitivity: Consistent sequencing may gradually enhance the body's insulin function, benefiting long‑term metabolic health Benefits of meal sequencing By adopting a meal sequencing approach, individuals with diabetes can experience several benefits, including: Better post-meal blood sugar control : Eating vegetables and protein before carbohydrates can slow down the digestion and absorption of glucose, reducing blood sugar spikes. Reduced insulin requirements: By regulating blood sugar levels, meal sequencing can help reduce the need for insulin medication. Improved overall diabetes management : Meal sequencing can be a valuable tool in managing diabetes, reducing the risk of complications, and improving overall health. Potential weight loss benefits: By controlling blood sugar levels and improving insulin sensitivity, meal sequencing can also support weight loss. Enhanced nutrient absorption: Eating a balanced meal with vegetables, protein, and complex carbohydrates can ensure optimal nutrient absorption. Also read | Natural herbs that help regulate blood sugar levels at home
Hindustan Times
a day ago
- Hindustan Times
TN Class 12 Supplementary Result 2025 on July 25, how to download Tamil Nadu HSE + 2 supply results
The Directorate of Government Examinations (DGE), Tamil Nadu will be releasing the results of HSE Second Year or Class 12 Supplementary Exam Results 2025 on Friday, July 25, 2025. Students who appeared in the exam will be able to check their results on the official website at TN Class 12 Supplementary Result 2025 will be declared on July 25, 2025. (HT file) An official notice issued by the DGE TN informed that students will be able to download their marksheets from the official website by afternoon. Students will need to click on the HSE Second Year Supplementary Exam Jun/Jul 2025 result link. Also read: UP Board Class 10, 12 compartment exams 2025 on July 26, check timing and more Students will need to enter their Roll Number and Date of Birth to download their marksheet. Meanwhile, students can also apply for a copy of answer sheet. To do so, they should visit the office of the Assistant Director of District Government Examinations concerned between July 28, 2025 and July 29, 2025, from 11 AM to 5 PM. Students will need to register by paying a fee of Rs.275/- for each subject. Also read: Student from shelter home celebrates first day of college with 16-km run to promote education and fitness The date to download the copy of the answer sheet will be informed later on the website. Further, candidates who have received copy of answer sheet will be notified later on the date to apply for re-sit/revaluation. Notably, the HSE+2 supplementary examinations 2025 were conducted from June 25 to July 2. Papers were held in single shifts, from 10 am to 1:15 pm. It may also be mentioned here that the DGE announced the annual HSE or 12th exam result on May 8, 2025. The exams were held from March 3 to 25. The overall pass percentage in the annual HSE +2 examination was 95.03 per cent. A total of 7,92,494 students appeared for the exam this year, of whom 7,53,142 passed. Also read: IIT Bombay launches certificate course in 'Supply Chain Analytics with AI & ML,' enrolments open; check details TN HSE +2 Supply Results 2025: Steps to download Candidates can check their results by following the steps mentioned below: Visit the official website at On the home page, click on the link to download to the HSE +2 Supplementary Results 2025. Enter your credentials to log in, and submit. Check your result displayed on the screen. Download and keep a printout of the same for future reference. For more details, students are advised to visit the official website of DGE TN.
